123 results on '"Hillen, Heinz"'
Search Results
2. Structure and Molecular Arrangement of Proteolipid Protein of Central Nervous System Myelin
3. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model
4. The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
5. Globular amyloid β-peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimerʼs disease
6. Structural characterization of a soluble amyloid [beta]-peptide oligomer
7. Is Science the Only Driver in Species Selection? An Internal Study to Evaluate Compound Requirements in the Minipig Compared to the Dog in Preclinical Studies
8. P4-195: Restoration of home cage activity in Tg2576 mice by immunotherapy with the Ab-oligomer selective antibody A-887755
9. Magnetic Resonance Imaging Detection and Time Course of Cerebral Microhemorrhages during Passive Immunotherapy in Living Amyloid Precursor Protein Transgenic Mice
10. P1-221: Age dependent A-beta-oligomer formation in Tg2576 mice monitored by using the A-beta-oligomer selective antibody A-887755
11. P3‐275: Abeta‐oligomer selective antibody A‐887755 exhibits a favorable profile for Alzheimer's disease immunotherapy compared to Abeta‐peptide unselective antibodies
12. Structural Characterization of a Soluble Amyloid β-Peptide Oligomer
13. Serine Protease Inhibitor Nafamostat Given Before Reperfusion Reduces Inflammatory Myocardial Injury by Complement and Neutrophil Inhibition
14. P2-318: Generation of amyloid-beta oligomer-specific antibodies using proteolytically truncated structural core units of amyloid-beta globulomer
15. P2-304: MRI detection and time course of cerebral microhemorrhages during Aβ antibody treatment in living APP transgenic mice
16. P2-483: Biophysical characterization of soluble amyloid-β peptide oligomers
17. P2‐352: Effects of anti‐Aβ oligomer treatment on synaptic density in young Tg2576 mice: A preclinical model for measuring Alzheimer's disease modification
18. IC-02-02: MRI detection and time course of cerebral microhemorrhages during Aβ antibody treatment in living APP transgenic mice
19. P1-410: Abeta globulomer - A useful synthetic tool to mimic an endogenous neurotoxic Abeta structure
20. O3-05-03: Therapeutic effects of passive immunization with an Aβ-oligomer- specific antibody in APP transgenic mice
21. Aβ-globulomers are formed independently of the fibril pathway
22. Amyloid β Oligomers (Aβ1–42Globulomer) Suppress Spontaneous Synaptic Activity by Inhibition of P/Q-Type Calcium Currents
23. Proteome analysis of myocardial tissue following ischemia and reperfusion—Effects of complement inhibition
24. P3–440: Effects of Aβ1–42 globulomer on electrophysiological properties of rat hippocampal neurons
25. Globular amyloid beta-peptide1-42 oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease
26. Monomeric Structures of the Zymogen and Active Catalytic Domain of Complement Protease C1r
27. Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits
28. Obesity Is Associated With Tissue-Specific Activation of Renal Angiotensin-Converting Enzyme In Vivo
29. ChemInform Abstract: Discovery and Synthesis of (S)‐3‐[2‐(3,4‐Dimethoxyphenyl)ethoxy] ‐2‐(4,6‐dimethylpyrimidin‐2‐yloxy)‐3,3‐diphenylpropionic Acid (LU 302872), a Novel Orally Active Mixed ETA/ETB Receptor Antagonist.
30. Discovery and Synthesis of (S)-3-[2-(3,4-Dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic Acid (LU 302872), a Novel Orally Active Mixed ETA/ETB Receptor Antagonist
31. Monoclonal Antibodies Against Human Endothelin-Converting Enzyme-1
32. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1)
33. Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies.
34. Structural Characterization of a Soluble Amyloid β-Peptide Oligomer.
35. Globular amyloid β-peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease.
36. Crystallization of human tumour necrosis factor
37. Age dependent A-beta-oligomer formation in Tg2576 mice monitored by using the A-beta-oligomer selective antibody A-887755
38. Pharmaceutical Proteins.
39. Amino-Acid Sequence of Human and Bovine Brain Myelin Proteolipid Protein (Lipophilin) is Completely Conserved.
40. Abeta-oligomer selective antibody A-887755 exhibits a favorable profile for Alzheimer's disease immunotherapy compared to Abeta-peptide unselective antibodies
41. Monomeric Structures of the Zymogen and Active Catalytic Domain of Complement Protease C1r Further Insights into the C1 Activation Mechanism
42. The Primary Structure of Bovine Brain Myelin Lipophilin (Proteolipid Apoprotein)
43. Primary Structure of the C-Terminal Cyanogen Bromide Fragments II, III and IV from Bovine Brain Proteolipid-Apoprotein
44. Lipophilin (Proteolipid Apoprotein) of Brain White Matter. Purification and Amino Acid Sequence Studies of the Four Tryptophan Fragments
45. Analysis of the Primary Structure of the Strongly Hydrophobic Brain Myelin Proteolipid Apoprotein (Lipophilin). Isolation and Amino Acid Sequence Determination of Proteolytic Fragments
46. P3-440: Effects of Aβ 1-42 globulomer on electrophysiological properties of rat hippocampal neurons
47. Lipophilin (Proteolipid Apoprotein) of Brain White Matter. Purification and Amino Acid Sequence Studies of the Four Tryptophan Fragments
48. Pharmaproteine
49. Primary Structure of the C-Terminal Cyanogen Bromide Fragments II, III and IV from Bovine Brain Proteolipid-Apoprotein
50. The Primary Structure of Bovine Brain Myelin Lipophilin (Proteolipid Apoprotein)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.